Trypanothione disulfide reductase (TryR) is an essential homodimeric enzyme of trypanosomatid parasites that has been validated as a drug target to fight human infections. Using peptides and peptidomimetics, we previously obtained proof of concept that disrupting protein-protein interactions at the dimer interface of TryR TryR offered an innovative and so far unexploited opportunity for the development of novel antileishmanial agents. Now, we show that linking our previous peptide prototype to selected hydrophobic moieties provides a novel series of small-molecule-peptide conjugates that behave as good inhibitors of both TryR activity and dimerization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308777 | PMC |
http://dx.doi.org/10.3390/ph14070689 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!